| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary target of propylparaben sodium is microorganisms, including bacteria, yeast, and molds. The compound acts as a broad-spectrum antimicrobial agent. Propylparaben sodium disrupts follicle growth and steroidogenic functions by altering cell cycle, apoptosis, and steroidogenic pathways. Its mechanism involves disrupting microbial cell processes, thereby extending product shelf life.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated the antimicrobial activity of propylparaben sodium against a broad spectrum of microorganisms. The compound is effective against bacteria, yeast, and molds. Propylparaben sodium has been shown to disrupt cell cycle and apoptosis pathways. Its in vitro activity supports its use as a preservative in various products.
|
| ln Vivo |
In vivo studies have shown that propylparaben sodium can disrupt follicle growth and steroidogenic functions. The compound has been studied for its effects on reproductive and endocrine systems. Propylparaben sodium is used as a pharmaceutical aid (antimicrobial preservative). Further studies are needed to fully characterize its in vivo effects.
|
| Enzyme Assay |
For antimicrobial activity testing, standard agar diffusion or broth microdilution methods are used. Bacteria, yeast, and molds are cultured on appropriate media and exposed to serial dilutions of propylparaben sodium. MIC values are determined after 24-48 hours of incubation. Standard protocols for antimicrobial preservative efficacy testing are described in the literature.
|
| Cell Assay |
For in vitro cell-based studies, various cell lines may be used to evaluate the compound's effects on cell cycle and apoptosis. Cells are cultured in appropriate media and treated with serial dilutions of propylparaben sodium. Cell viability, cell cycle distribution, and apoptosis markers are assessed. Standard protocols for cell-based assays are described in the literature.
|
| Animal Protocol |
In vivo animal studies for propylparaben sodium have been conducted to evaluate its effects on reproductive and endocrine systems. Animal models are used to assess the compound's effects on follicle growth and steroidogenic functions. The compound is administered via oral or other routes. Standard protocols for in vivo toxicology studies are described in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of propylparaben sodium have been characterized. The compound is freely soluble in water, sparingly soluble in ethanol, and practically insoluble in methylene chloride. It has a pKa of 8.46 at 20°C. The compound is hygroscopic. Specific PK parameters such as half-life and bioavailability have been reported in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for propylparaben sodium indicate that it causes serious eye damage (H318, 93.2%) and is harmful to aquatic life with long lasting effects (H412, 22.4%). The compound may disrupt endocrine functions. Standard toxicology studies have been conducted for regulatory purposes.
|
| References |
|
| Additional Infomation |
Propylparaben sodium is a widely used antimicrobial preservative in cosmetics, pharmaceuticals, and foods. It is a pharmaceutical aid (antimicrobial preservative). The compound is often used in combination with other parabens, such as methylparaben and ethylparaben, to enhance effectiveness. Propylparaben sodium is available as a research compound for preservative and toxicology studies.
|
| Molecular Formula |
C10H11NAO3
|
|---|---|
| Molecular Weight |
202.18
|
| Exact Mass |
202.06
|
| CAS # |
35285-69-9
|
| Related CAS # |
Propylparaben;94-13-3;Propylparaben-d7;1246820-92-7;Propylparaben-d4;1219802-67-1
|
| PubChem CID |
23679044
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
294.3ºC at 760 mmHg
|
| Melting Point |
96-97ºC
|
| Flash Point |
124.6ºC
|
| LogP |
2.397
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
165
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[O-]C1=CC=C(C(OCCC)=O)C=C1.[Na+]
|
| InChi Key |
IXMINYBUNCWGER-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C10H12O3.Na/c1-2-7-13-10(12)8-3-5-9(11)6-4-8;/h3-6,11H,2,7H2,1H3;/q;+1/p-1
|
| Chemical Name |
sodium;4-propoxycarbonylphenolate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9461 mL | 24.7304 mL | 49.4609 mL | |
| 5 mM | 0.9892 mL | 4.9461 mL | 9.8922 mL | |
| 10 mM | 0.4946 mL | 2.4730 mL | 4.9461 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.